PARK7/DJ1 is a ubiquitously expressed protein involved in various cellular processes including cell proliferation, RNA-binding, and oxidative stress.
The protein has been found to colocalize within a subset of pathologic tau inclusions in a diverse group of neurodegenerative disorders known as tauopathies (Rizzu et al.
2004).
Defects in PARK7/DJ1 are the cause of autosomal recessive early-onset Parkinson's disease 7 (PARK7).
Parkinson's disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years.
The disease is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability.
The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.
PARK7 is characterized by onset before 40 years and slow progression.
It has also been suggested that PARK7/DJ1 is a mitogen dependent oncogene product involved in Ras related signal transduction pathways.
Applications:Suitable for use in FLISA and Western Blot.
Other applications not tested.
Recommended Dilution:Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only.
For long-term storage and to avoid repeated freezing and thawing, aliquot and store at -20°C.
Aliquots are stable for 12 months at -20°C.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Further dilutions can be made in assay buffer.
FITC conjugates are sensitive to light.
仕様
Size：100ug
Host：rabbit
Source Antibody：human
Grade：Affinity Purified
Purity：Purified by Protein G affinity chromatography.
Form：Supplied as a liquid in 0.01M PBS, PH 7.4, 0.03% Proclin 300, 50% glycerol. Labeled with fluorescein isothiocyanate (FITC).
Specificity：Recognizes human PARK7.
Isotype：IgG
Calc Applications Abbrev：FLISA WB
Calc Crossreactivity：Hu
Immunogen：Recombinant corresponding to human PARK7.
